TNXP Tonix Pharmaceuticals Holding: Enterprise Value to EBITDA Ratio
Tonix Pharmaceuticals (TNXP) relies on diversified CNS research and government support to maintain liquidity. Management is coordinating the parallel launch of multiple clinical stages, although frequent secondary offerings and test failures are weakening patent protection. This daily price action reflects these factors, recording the 0.00 metric, which underscores the company's current fundamental state.
Comprehensive metric breakdowns and analytics for tonixpharma.com (TNXP)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Tonix Pharmaceuticals|TNXP - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Tonix Pharmaceuticals Holding Corp.|TNXP - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio Tonix Pharmaceuticals Holding|TNXP - Long-Term Debt|Company Short-Term Debt Tonix Pharmaceuticals|Quick Ratio tonixpharma.com
- financial results and valuation multiples details:
TNXP - Net Financial Result|Future Profit Tonix Pharmaceuticals|TNXP - Price to Earnings Multiple|Projected Price to Earnings Tonix Pharmaceuticals|TNXP - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tonix Pharmaceuticals Holding|TNXP - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Tonix Pharmaceuticals|TNXP - Earnings per share for the trailing year|Quarterly EPS earnings growth tonixpharma.com|TNXP - Earnings growth in current year|Net earnings per share growth forecast for next year Tonix Pharmaceuticals
- company sales and revenue statistics:
General company analysis:TNXP (Tonix Pharmaceuticals Inc.)
For Tonix Pharmaceuticals (TNXP), which competes in the pain management drug segment, fluctuations in the company's EV/EBITDA ratio reflect the business value relative to its operational efficiency. This multiple is calculated as the ratio of total enterprise value to earnings before interest, taxes, depreciation, and amortization. The formula's high sensitivity to debt load reveals risks associated with the acceleration of costly research. The stability of this indicator determines the asset's ability to withstand market shocks.
Competitor analysis
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|ANI Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio MNKD (MannKind Corp)|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Pacira Corp|ARS Pharmaceuticals (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation TBPH|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|scPharma (SCPH) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TECX (Tectonic Therapeutic, Inc.)|sxtchina.com - Enterprise Value to Operating Income Before Depreciation|Eupraxia Pharmaceuticals Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHST|EXOZ - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ORMP|ENTX: EV/EBITDA Multiple|MindWalk Therapeutics - Business Value to Operating Income Before Depreciation|ABVC (ABVC BioPharma) - EV/EBITDA Multiple|EV/EBITDA Multiple cumberlandpharma.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Quantum BioPharma (QNTM)|FGEN (FibroGen Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Telomir Pharma TELO|RANI - Enterprise Value to EBITDA Ratio|Synergy CHC Corporation - EV/EBITDA Multiple|RLYB - EV/EBITDA Multiple|LEXX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pulmatrix Inc|PTHL (Pheton Holdings Limited) - EV/EBITDA Multiple|Company Value to EBITDA Aptorum APM|Enterprise Value to EBITDA Ratio LYRA (Lyra Therapeutics, Inc.)|EV/EBITDA Multiple impactbiomedinc.com (IBO)|TNF Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio YCBD (cbdMD Inc.)|PainReform Limited - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Altamira Therapeutics CYTO|LIPO: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio optinose.com|PIRS (Pieris Pharmaceuticals, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Procaps Group|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization QLI (Qilian International Corp)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|Total Company Value to Operating Income Before Depreciation Ratio tffpharma.com (TFFP)
